as informed in latimes
Pfizer to acquire cancer drug company Medivation in $14-billion deal
Pfizer to acquire cancer drug company Medivation in $14-billion deal
Pfizer is buying the cancer drug company Medivation in a deal valued at about $14 billion, the companies announced Monday.Pfizer Inc. will pay $81.50 per Medivation share.That's a 21% premium to the San Francisco biotech company's Friday closing price of $67.19.Medivation Inc.'s stock soared more than 19% before Monday's opening bell on Wall Street.
additionally bostonglobe
Pfizer to pay $14b to acquire cancer drug company Medivation
Pfizer to pay $14b to acquire cancer drug company Medivation
Pfizer Inc. agreed to buy Medivation Inc. in a deal that values the company at about $14 billion and leaves French drugmaker Sanofi jilted.Pfizer will pay $81.50 a share in cash, the companies said in a statement on Monday.Shares of Medivation, which closed at $67.16 on Friday, climbed about 20 percent to $80.58 in early U.S. trading.AdvertisementBy acquiring Medivation, Pfizer gains a blockbuster prostate-cancer treatment, Xtandi, that's already approved for sale in the U.S. and elsewhere, and that analysts project will generate $1.33 billion in annual sales by 2020.
not to mention wbaltv
Pfizer buys cancer drug maker Medivation for $14 billion
Pfizer buys cancer drug maker Medivation for $14 billion
Pfizer announced a $14 billion deal for Medivation, a biotech company that makes an important cancer drug.Medivation's portfolio includes Xtandi, a drug that treats prostate cancer.Pfizer said Xtandi generated approximately $2.2 billion in worldwide sales, and the purchase should add to its earnings per share immediately.Pfizer will pay $81.50 in cash for each Medivation share, a 21% premium over Friday's closing price.
No comments:
Post a Comment